-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

The Approach of HMA + ven With or Without BMT for All patients

Program: Education Program
Session: Have We Optimized Therapy Yet for Patients with AML?
Hematology Disease Topics & Pathways:
Combination therapy, Therapies
Sunday, December 10, 2023, 4:30 PM-5:45 PM

Tara L Lin, MD

University of Kansas Medical Center, Fairway, KS

Disclosures: Lin: Bio-path Holdings: Consultancy, Research Funding; Astellas Pharma: Consultancy, Research Funding; Celyad: Research Funding; Aptevo Therapeutics: Research Funding; Cleave Biosciences: Research Funding; Ciclomed: Research Funding; Jazz Pharmaceuticals: Research Funding.

OffLabel Disclosure: The Approach of HMA + ven With or Without BMT for All Patients with AML

See more of: Have We Optimized Therapy Yet for Patients with AML?
See more of: Education Program
<< Previous Presentation | Next Presentation >>